期刊文献+

尿激酶型纤溶酶原激活物(uPA)及其抑制物-1(PAI-1)在子宫内膜癌中的表达及其临床病理意义 被引量:4

Expressions of urinary plasminogen activator(uPA) and its inhibitor-1(PAI-1) in endometrial cancer and their clinicopathological significances
原文传递
导出
摘要 目的:探讨尿激酶型纤溶酶原激活物(uPA)及其抑制物-1(PAI-1)在子宫内膜癌发生、发展中的作用。方法:子宫内膜癌标本61例,同时取患者相应的癌旁正常子宫内膜组织作为对照。应用组织芯片法与免疫组织化学法,检测每例子宫内膜癌标本和正常子宫内膜组织中uPA及其抑制物PAI-1的表达情况。结果:PAI-1在子宫内膜癌组织中的表达率为37.7%(23/61),在正常子宫内膜组织中的表达率为60.7%(37/61),两组间差异有统计学意义(χ2=6.428,P<0.05);PAI-1的表达与患者的年龄、组织类型、肿瘤组织学分级、淋巴结转移无关(均P>0.05),但与临床病理分期有关(P<0.05)。uPA在子宫内膜癌组织中的阳性表达率为42.6%(26/61),在正常子宫内膜组织中的阳性表达率为21.3%(13/61),两组间差异有统计学意义(χ2=6.369,P<0.05);uPA的表达与患者的年龄、组织类型、肿瘤组织学分级无关(均P>0.05),但与肿瘤临床病理分期和肿瘤淋巴结转移有关(P<0.05)。此外,uPA和PAI-1在子宫内膜癌中阳性表达差异无统计学意义(P>0.05)。结论:uPA和PAI-1的异常表达在子宫内膜癌的发生中有重要作用,PAI-1的低表达和uPA的高表达与子宫内膜癌临床病理进展有关。 Objective : To explore the roles of urinary plasminogen activator (uPA) and its inhibitor - 1 ( PAl - 1 ) in occurrence and development of endometrial cancer. Methods: Sixty - one samples of endometrial cancer were collected from the hospital, at the same time, the samples of normal endometrium tissue adjacent endomctrial cancer were obtained as control group. Tissue microarray and immuno- histochemical method were used to detect the expression levels of uPA and PAI - 1 in endometrial cancer samples and normal endometrium samples. Results: The expression rates of PAI- 1 in endometrial cancer samples and normal endometrium samples were 37.7% (23/61) and 60. 7% (37/61), respectively, there was statistically significant difference between the two groups (χ^2 = 6. 428, P 〈 0.05 ) . There was no correlation between PAI- 1 expression and age, histological type, histological grade, and lymph node metastasis ( P 〉 0. 05 ) , but PAI- 1 expression was correlated with clinicopathological stage ( P 〈 0. 05 ) . The expression rates of uPA in endomctrial cancer samples and normal endometrium samples were 42. 6% (26/61) and 21.3% ( 13/61 ) , respectively, there was statistically significant difference be- tween the two groups (χ^2 = 6. 369, P 〈 0. 05 ) . There was no correlation between uPA expression and age, histological type, and histologi- cal grade ( P 〉 0.05 ) , but uPA expression was correlated with clinicopathological stage and lymph node metastasis ( P 〈 0. 05 ) . In addi- tion, there was no statistically significant difference in the positive expression rates of uPA and PAI - 1 in endometrial cancer samples. Conclusion: The abnormal expressions of uPA and PAI- 1 play important roles in the occurrence of endometrial cancer, the low expression of PAI- 1 and high expression of uPA are related to the clinieopathological progression of endometrial cancer.
出处 《中国妇幼保健》 CAS 北大核心 2012年第18期2824-2826,共3页 Maternal and Child Health Care of China
关键词 子宫内膜癌 UPA PAI-1 组织芯片 免疫组织化学 Endometrial cancer uPA PAI - 1 Tissue microarray Immunohistochemistry
  • 相关文献

参考文献8

  • 1Astedt B, Holmberg L. Immunological identify of urokinase and ovarian carcinoma plasminogen activator released in tissue cul- ture [J]. Nature, 1976, 161:595.
  • 2Cajot JE, Schleuning WK, Medcalf RP et al. Mouse L cells ex- pressing human prourokinase type plasminogen activator: effects on extracellular matrix degradation and invasion[J]. Cell Biology, 1989, 109:915.
  • 3Vassalli JD, Sappino AP, Belin D et al. A cellular binding site for the Mr 55 000 form of human urokinase plasminogen activa- tor [J] . J Cell Biol, 1985, 100:86.
  • 4Mazzieri R, Masiero L, Zanetta L et al. Control of type IV col- lagenase activity by components of the urokinase - plasmin sys- tem : a regulatory mechanism with cell - bound reactants [J].EMBO J, 1997, 16 (9): 2319.
  • 5Steiner E, Pollow K, Hasenclever D et al. Role of urokinase - type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI - 1 - 1 ) for prognosis in endometrial cancer [J] . Gynecol Oncol, 2008, 108 (3): 569.
  • 6Su CK, Yeh KT, Yeh CB et al. Genetic polymorphism of the plasminogen activator inhibitor - 1 is associated with an in- creased risk of endometrial cancer[J]. J Surg Oncol, 2011, 104 (7): 755.
  • 7Nordengren J, Fredstorp Lidebring M, Bendahl POet al. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI - 1 - 2) is an independent marker for shorter progression free survival in patients with early stage endometrial cancer [J]. Int J Cancer, 2002, 97 (3) : 379.
  • 8Fredstorp - Lidebring M, Bendahl PO, Brtinner Net al. Uroki- nase plasminogen activator and its inhibitor, PAI - 1 - 1, in association with progression -free survival in early stage endo- metrial cancer [J] . Eur J Cancer, 2001, 37 (18): 2339.

同被引文献39

  • 1Hildenbrand R, Allgayer H, Marx A, et al.Modulators of the urokinase-type plasminogen activation system for cancer[J].Expert Opin Investig Drugs, 2010, 19(5): 641-652.
  • 2Nagi D K, McCormack L J, Mohamed-Ali V, et al.Diabetic retinopathy, promoter(4G/5G)polymorphism ofPAI-1 gene, andPAI-1 activity in Pima Indians with type 2 diabetes[J].Diabetes Care, 1997, 20(8): 1304-1309.
  • 3Liotta L A.Cancer cell invasion and metastasis[J].Scientific American, 1992, 266(2): 54-59, 62-63.
  • 4J Lijnen H R.Pleiotropic functions of plasminogen activator inhibitor-1[J].J Yhmmb Haemost, 2005, 3(1): 35-45.
  • 5Lee J H, Kim Y, Choi J W, et al.Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis[J].Arch Med Res, 2013, 44(1): 39-45.
  • 6Jorgenson E, Deitcher S R, Cicek M, et al.Plasminogen activator inhibitor type-1(PAI-1)polymorphism 4G/5G is associated with prostate cancer among men with a positive family history[J].Prostate, 2007, 67(2): 172-177.
  • 7Castello R, Espana F, Vazquez C, et al.Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity[J].Thromb Res, 2006, 117(10): 487-492.
  • 8Botkjaer KA,Deryugina EI,Dupont DM,et al.Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism[J].Molecular Cancer Research,2012,10(12):1532-1543.
  • 9Gupta V,Chitranshi N,You Y,et al.Brain derived neurotrophic factor is involved in the regulation of glycogen synthase kinase3β(GSK3β)signalling[J].Biochemical and biophysical research communications,2014,454(3):381-386.
  • 10Harbeck N,Schmitt M,Meisner C,et al.Ten-year analysis of the prospective multicentre Chemo-N0trial validates American Society of Clinical Oncology(ASCO)-recommended biomarkers uPA and PAI-1for therapy decision making in node-negative breast cancer patients[J].European Journal of Cancer,2013,49(8):1825-1835.

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部